Sugi Predict

Sugi Predict / Compounds / SCHEMBL2639604

SCHEMBL2639604

SCHEMBL2639604

O=C(O)C(Nc1cccc(Cl)c1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.54
▸ RAB9A P51151 4/20 0.54
▸ MEN1 O00255 4/20 0.54
▸ KMT2A Q03164 4/20 0.54
▸ MAPT P10636 4/20 0.54
▸ LMNA P02545 3/20 0.54
▸ HTT P42858 3/20 0.54
▸ ALDH1A1 P00352 5/20 0.52
▸ HPGD P15428 1/20 0.52
▸ CASR P41180 1/20 0.51
▸ KEAP1 Q14145 1/20 0.49
▸ NFE2L2 Q16236 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ MDM2 Q00987 1/20 0.46
▸ EGFR P00533 1/20 0.46
▸ MMP1 P03956 1/20 0.46
▸ MMP2 P08253 1/20 0.46
▸ MMP9 P14780 1/20 0.46
▸ MAOA P21397 1/20 0.46
▸ MAOB P27338 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9298095 0.90 KEAP1 (0.52) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL9298091 0.90 KEAP1 (0.52) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL7576844 0.87 ALDH1A1 (0.56) RAB9AMEN1KMT2AMAPTLMNA
SCHEMBL11207673 0.83 MEN1 (0.49) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL2483521 0.82 FPR2 (0.49) MAPTLMNAALDH1A1SMN1; SMN2KDM4E
SCHEMBL146704 0.82 FPR2 (0.49) MAPTLMNAALDH1A1SMN1; SMN2KDM4E
SCHEMBL2483519 0.82 FPR2 (0.49) MAPTLMNAALDH1A1SMN1; SMN2KDM4E
SCHEMBL7584703 0.82 NPC1 (0.53) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL7574163 0.82 CYP3A4 (0.55) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL1696047 0.81 MDM2 (0.48) NPC1RAB9AMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170157010-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS ASSOCIATED WITH DAMAGE INDUCED BY FREE RADICALS GLYCADIA, INC. (US) 2017-06-08 — — US claimed
US-8962020-B2 Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid Glycadia Inc. (US) 2015-02-24 — — US claimed
US-20140030325-A1 LONG-ACTING AND CONTROLLED RELEASE FORMULATIONS OF 2-[(3-CHLOROPHENYL) AMINO] PHENYLACETIC ACID GLYCADIA, INC. (US) 2014-01-30 — — US claimed
JP-4833468-B2 — — 2011-12-07 — — JP claimed
US-6552077-B2 Kidney disorders EXOCELL, INC. 2003-04-22 — — US claimed
EP-1242069-A2 ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES EXOCELL, INC. (US) 2002-09-25 — — EP claimed
WO-2001003684-A2 ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES EXOCELL, INC. (US) 2001-01-18 — — WO claimed
US-20170157010-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS ASSOCIATED WITH DAMAGE INDUCED BY FREE RADICALS GLYCADIA, INC. (US) 2017-06-08 — — US disclosed
US-20170157010-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS ASSOCIATED WITH DAMAGE INDUCED BY FREE RADICALS GLYCADIA, INC. (US) 2017-06-08 — — US disclosed
US-8962020-B2 Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid Glycadia Inc. (US) 2015-02-24 — — US disclosed
US-8962020-B2 Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid Glycadia Inc. (US) 2015-02-24 — — US disclosed
US-8962020-B2 Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid Glycadia Inc. (US) 2015-02-24 — — US disclosed
US-20140030325-A1 LONG-ACTING AND CONTROLLED RELEASE FORMULATIONS OF 2-[(3-CHLOROPHENYL) AMINO] PHENYLACETIC ACID GLYCADIA, INC. (US) 2014-01-30 — — US disclosed
US-20140030325-A1 LONG-ACTING AND CONTROLLED RELEASE FORMULATIONS OF 2-[(3-CHLOROPHENYL) AMINO] PHENYLACETIC ACID GLYCADIA, INC. (US) 2014-01-30 — — US disclosed
US-20080255236-A1 Methods and Composition Comprising 2-[(3-Chlorophenyl)Amino] Phenylacetic Acid for Alzheimer's Disease GLYCADIA, INC. (US) 2008-10-16 — — US disclosed
EP-1242069-B1 ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES EXOCELL INC (US) 2005-06-29 — — EP disclosed
US-6552077-B2 Kidney disorders EXOCELL, INC. 2003-04-22 — — US disclosed
EP-1242069-A2 ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES EXOCELL, INC. (US) 2002-09-25 — — EP disclosed
US-20010034359-A1 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies EXOCELL, INC. 2001-10-25 — — US disclosed
WO-2001003684-A2 ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES EXOCELL, INC. (US) 2001-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034359-A1 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies ALB, AGER, TTR NPC1 2335/4885RAB9A 3043/4885MEN1 3564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.